RT Journal Article
SR Electronic
T1 Antigen test swabs are comparable to nasopharyngeal swabs for sequencing of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.09.22276150
DO 10.1101/2022.06.09.22276150
A1 Hassouneh, Sayf Al-Deen
A1 Trujillo, Alexa
A1 Ali, Sobur
A1 Cella, Eleonora
A1 Johnston, Catherine
A1 DeRuff, Katherine C.
A1 Sabeti, Pardis C.
A1 Azarian, Taj
YR 2022
UL http://medrxiv.org/content/early/2022/06/14/2022.06.09.22276150.abstract
AB Viral genomic surveillance has been integral in the global response to the SARS-CoV-2 pandemic. Surveillance efforts rely on the availability of representative clinical specimens from ongoing testing activities. However, testing practices have recently shifted due to the widespread availability and use of rapid antigen tests, which could lead to gaps in future monitoring efforts. As such, genomic surveillance strategies must adapt to include laboratory workflows that are robust to sample type. To that end, we compare the results of RT-qPCR and viral genome sequencing using samples from positive BinaxNOW™ COVID-19 Antigen Card swabs (N=555) to those obtained from previously collected nasopharyngeal (NP) swabs used for nucleic acid amplification testing (N=135). We show that swabs obtained from antigen cards are comparable in performance to clinical excess samples from NP swabs, providing a viable alternative. This validation permits the reliable expansion of viral genomic surveillance to cases identified in the clinic or home setting where rapid antigen tests are used.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by a grant from The Rockefeller Foundation to the University of Florida and the University of Central Florida in order to accelerate regional genomic surveillance. The views and findings are those of the authors and not those of the funder (The Rockefeller Foundation).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed by the University of Central Florida Institutional Review Board and received a non-human subjects determination.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors